Modality.AI and Target ALS are partnering on a clinical study of AI as a way to assess changes in speech and motor function ...

What is contentment, and is it even possible with the daily struggles of ALS? Columnist Kristin Neva offers her observations as a caregiver.

The new patent covers Neurosense's formulation of PrimeC, a fixed-dose combo of an approved antibiotic and anti-inflammatory.

ProJenX teamed with Unlearn to create digital twins of ALS patients as a placebo group in open-label extension of Phase 1 ...

Clene will have an in-person meeting with the FDA before the end of November to discuss a potential CNM-Au8 accelerated ...

The Mayo Clinic was awarded $12 million to support a study that will give ALS patients access to the investigational therapy ...

Columnist Juliet Taylor chats with Roon CEO and co-founder Vikram Bhaskaran about this new ALS app designed for patients and ...

Living well with ALS means we must be mindful, writes columnist Dagmar Munn, who shares an anecdote about an unplanned long walk.

Mabylon has received grants from Target ALS and the ALS Association to develop human-derived antibodies to help restore ...

A group of eight molecules in the blood can be used as a biomarker to distinguish ALS from other neurodegenerative conditions ...

Columnist Juliet Taylor reflects on how the power of music helped her and her late husband, Jeff, navigate the difficulties ...

Amprion was awarded a $100,000 research grant to support studies on the causes of sporadic ALS that could improve diagnosis ...